Fosun Pharma's Subsidiary Gains Approval for HLX109 Injection Clinical Trial in Australia
Stock News
Nov 04
Fosun Pharma (600196.SH) has announced that its controlling subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively "Henlius") have received approval from the relevant Human Research Ethics Committee for the Phase I clinical trial protocol of HLX109 injection (an anti-IL1RAP monoclonal antibody) for the treatment of generalized pustular psoriasis, and have also completed filing with Australia's Therapeutic Goods Administration. This marks the first clinical trial authorization obtained globally for this drug.
Henlius plans to commence related clinical research for this drug in Australia once conditions are met.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.